Birmingham Capital Management Co. Inc. AL Sells 13,063 Shares of Pfizer Inc. (NYSE:PFE)

Birmingham Capital Management Co. Inc. AL reduced its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 7.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 173,587 shares of the biopharmaceutical company's stock after selling 13,063 shares during the quarter. Pfizer accounts for 1.7% of Birmingham Capital Management Co. Inc. AL's holdings, making the stock its 23rd largest position. Birmingham Capital Management Co. Inc. AL's holdings in Pfizer were worth $4,605,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Norges Bank purchased a new stake in shares of Pfizer during the fourth quarter worth approximately $2,328,986,000. Charles Schwab Investment Management Inc. raised its position in Pfizer by 19.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock valued at $4,124,330,000 after purchasing an additional 25,315,159 shares during the period. Starboard Value LP purchased a new position in Pfizer during the fourth quarter worth about $407,730,000. Raymond James Financial Inc. acquired a new stake in Pfizer in the 4th quarter valued at approximately $274,694,000. Finally, Massachusetts Financial Services Co. MA lifted its stake in Pfizer by 7.5% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock worth $2,029,604,000 after purchasing an additional 5,350,381 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. UBS Group boosted their target price on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. The Goldman Sachs Group reiterated a "neutral" rating and issued a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Citigroup restated a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Finally, Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $29.17.

Pfizer Price Performance

Pfizer stock traded up $0.11 during mid-day trading on Friday, hitting $23.56. The company's stock had a trading volume of 15,507,838 shares, compared to its average volume of 41,006,594. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The stock has a market capitalization of $133.92 billion, a P/E ratio of 16.71, a P/E/G ratio of 0.64 and a beta of 0.58. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock's fifty day moving average price is $23.16 and its two-hundred day moving average price is $25.09.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. During the same quarter last year, the firm posted $0.82 earnings per share. Pfizer's revenue was down 7.8% compared to the same quarter last year. Research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.30%. The ex-dividend date is Friday, May 9th. Pfizer's dividend payout ratio (DPR) is currently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.